{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:22:28Z","timestamp":1784931748415,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To compare three commonly used low-molecular-weight heparins (LWMHs) in the treatment of recurrent spontaneous abortion (RSA) by evaluating the anti-Xa peak levels and adverse reactions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this single-center, observational study, we enrolled 310 patients with RSA in whom anti-Xa levels were measured during pregnancy. Patients were divided into three groups according to the LMWH they used: the nadroparin group, enoxaparin group and dalteparin group. We compared the peak anti-Xa levels and the coagulation status of each group, and analyzed the incidence of adverse reactions, including local allergy, liver and renal dysfunction, and the impact on platelet.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients in the enoxaparin group had a higher anti-Xa peak level than those in the nadroparin group (0.80\u2009\u00b1\u20090.22\u2009IU\/ml vs. 0.61\u2009\u00b1\u20090.24\u2009IU\/ml; <jats:italic>P<\/jats:italic>\u2009&lt;\u2009\u00a00.0001), although most patients in the three groups reached the target concentration of anti-Xa. Furthermore, patients in the enoxaparin group had a more stable anti-Xa levels during pregnancy. In addition, patients in the nadroparin group had a higher rate of local allergy than those in the enoxaparin group (60.5% vs. 42.5%; <jats:italic>P<\/jats:italic>\u2009=\u20090.004) and those in the dalteparin group (60.5% vs. 33.3%; <jats:italic>P<\/jats:italic>\u2009=\u20090.002). Further examination by the type of local allergy indicated a dramatic difference in pruritus and induration between the nadroparin group and the other two groups. No difference was found in the incidence of liver and renal dysfunction and thrombocytopenia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Compared with nadroparin and daltepatin, enoxaparin showed a better performance regarding anti-Xa levels and the incidence of adverse reactions in the treatment of RSA.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12884-021-04161-1","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T09:09:00Z","timestamp":1633597740000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: a single-center, observational study"],"prefix":"10.1186","volume":"21","author":[{"given":"Wenxin","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaohong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congcong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"issue":"13","key":"4161_CR1","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1111\/j.1471-0528.2008.01943.x","volume":"115","author":"S Bhattacharya","year":"2008","unstructured":"Bhattacharya S, Townend J, Shetty A, Campbell D, Bhattacharya S. Does miscarriage in an initial pregnancy lead to adverse obstetric and perinatal outcomes in the next continuing pregnancy? BJOG. 2008;115(13):1623\u20139.","journal-title":"BJOG"},{"issue":"9535","key":"4161_CR2","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S0140-6736(06)69204-0","volume":"368","author":"R Rai","year":"2006","unstructured":"Rai R, Regan L. Recurrent miscarriage. Lancet. 2006;368(9535):601\u201311.","journal-title":"Lancet"},{"issue":"2","key":"4161_CR3","first-page":"1973","volume":"8","author":"M Wu","year":"2015","unstructured":"Wu M, Liu P, Cheng L. Galectin-1 reduction and changes in T regulatory cells may play crucial roles in patients with unexplained recurrent spontaneous abortion. Int J Clin Exp Pathol. 2015;8(2):1973\u20138.","journal-title":"Int J Clin Exp Pathol"},{"key":"4161_CR4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/1741-7015-11-154","volume":"11","author":"EC Larsen","year":"2013","unstructured":"Larsen EC, Christiansen OB, Kolte AM, Macklon N. New insights into mechanisms behind miscarriage. BMC Med. 2013;11:154.","journal-title":"BMC Med"},{"issue":"4","key":"4161_CR5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.fertnstert.2004.12.018","volume":"83","author":"OB Christiansen","year":"2005","unstructured":"Christiansen OB, Nybo Andersen AM, Bosch E, Daya S, Delves PJ, Hviid TV, et al. Evidence-based investigations and treatments of recurrent pregnancy loss. Fertil Steril. 2005;83(4):821\u201339.","journal-title":"Fertil Steril"},{"key":"4161_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1546-0096-12-47","volume":"12","author":"I Pagnini","year":"2014","unstructured":"Pagnini I, Simonini G, Cavalli L, la Marca G, Iuliano A, Brandi ML, et al. Bone status of children born from mothers with autoimmune diseases treated during pregnancy with prednisone and\/or low molecular weight heparin. Pediatr Rheumatol Online J. 2014;12:47.","journal-title":"Pediatr Rheumatol Online J"},{"key":"4161_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.thromres.2015.11.026","volume":"137","author":"E Shomer","year":"2016","unstructured":"Shomer E, Katzenell S, Zipori Y, Rebibo-Sabbah A, Brenner B, Aharon A. Microvesicles of pregnant women receiving low molecular weight heparin improve trophoblast function. Thromb Res. 2016;137:141\u20137.","journal-title":"Thromb Res"},{"issue":"5","key":"4161_CR8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/aji.12348","volume":"73","author":"L Luley","year":"2015","unstructured":"Luley L, Schumacher A, Mulla MJ, Franke D, Lottge M, Fill Malfertheiner S, et al. Low molecular weight heparin modulates maternal immune response in pregnant women and mice with thrombophilia. Am J Reprod Immunol. 2015;73(5):417\u201327.","journal-title":"Am J Reprod Immunol"},{"issue":"6","key":"4161_CR9","first-page":"1037","volume":"64","author":"GL Xu","year":"2018","unstructured":"Xu GL, Hu XF, Han YM, Wei AW. Clinical efficacy of low molecular heparin on unexplained recurrent spontaneous abortion. Clin Lab. 2018;64(6):1037\u201340.","journal-title":"Clin Lab"},{"issue":"4","key":"4161_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.rbmo.2017.06.018","volume":"35","author":"A Rottenstreich","year":"2017","unstructured":"Rottenstreich A, Amsalem H, Kleinstern G, Kalish Y. Outcomes of threatened abortions after anticoagulation treatment to prevent recurrent pregnancy loss. Reprod BioMed Online. 2017;35(4):461\u20137.","journal-title":"Reprod BioMed Online"},{"issue":"24","key":"4161_CR11","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1161\/01.CIR.103.24.2994","volume":"103","author":"J Hirsh","year":"2001","unstructured":"Hirsh J, Anand SS, Halperin JL, Fuster V, American Heart A. Guide to anticoagulant therapy: heparin : a statement for healthcare professionals from the American Heart Association. Circulation. 2001;103(24):2994\u20133018.","journal-title":"Circulation"},{"issue":"5","key":"4161_CR12","first-page":"807","volume":"99","author":"E Gray","year":"2008","unstructured":"Gray E, Mulloy B, Barrowcliffe TW. Heparin and low-molecular-weight heparin. Thromb Haemost. 2008;99(5):807\u201318.","journal-title":"Thromb Haemost"},{"key":"4161_CR13","doi-asserted-by":"publisher","first-page":"100613","DOI":"10.1016\/j.blre.2019.100613","volume":"39","author":"G Spadarella","year":"2020","unstructured":"Spadarella G, Di Minno A, Donati MB, Mormile M, Ventre I, Di Minno G. From unfractionated heparin to pentasaccharide: paradigm of rigorous science growing in the understanding of the in vivo thrombin generation. Blood Rev. 2020;39:100613.","journal-title":"Blood Rev"},{"key":"4161_CR14","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.2741\/4462","volume":"21","author":"A Onishi","year":"2016","unstructured":"Onishi A, St Ange K, Dordick JS, Linhardt RJ. Heparin and anticoagulation. Front Biosci (Landmark Ed). 2016;21:1372\u201392.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"3 Suppl","key":"4161_CR15","doi-asserted-by":"publisher","first-page":"188S","DOI":"10.1378\/chest.126.3_suppl.188S","volume":"126","author":"J Hirsh","year":"2004","unstructured":"Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3 Suppl):188S\u2013203S.","journal-title":"Chest"},{"issue":"9","key":"4161_CR16","first-page":"799","volume":"122","author":"M Laposata","year":"1998","unstructured":"Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med. 1998;122(9):799\u2013807.","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"4161_CR17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1177\/1078155217727140","volume":"25","author":"G Dranitsaris","year":"2019","unstructured":"Dranitsaris G, Shane LG, Woodruff S. Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: a systematic literature review of efficacy and cost-effectiveness. J Oncol Pharm Pract. 2019;25(1):68\u201375.","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"4161_CR18","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/TA.0000000000000087","volume":"76","author":"ME Droege","year":"2014","unstructured":"Droege ME, Mueller EW, Besl KM, Lemmink JA, Kramer EA, Athota KP, et al. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients. J Trauma Acute Care Surg. 2014;76(2):450\u20136.","journal-title":"J Trauma Acute Care Surg"},{"issue":"5","key":"4161_CR19","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/j.1538-7836.2012.04669.x","volume":"10","author":"SW Rathbun","year":"2012","unstructured":"Rathbun SW, Aston CE, Whitsett TL. A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. J Thromb Haemost. 2012;10(5):833\u20139.","journal-title":"J Thromb Haemost"},{"key":"4161_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/bs.pmbts.2019.02.003","volume":"163","author":"C Hao","year":"2019","unstructured":"Hao C, Sun M, Wang H, Zhang L, Wang W. Low molecular weight heparins and their clinical applications. Prog Mol Biol Transl Sci. 2019;163:21\u201339.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"4161_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.carbpol.2014.01.100","volume":"106","author":"RG Ingle","year":"2014","unstructured":"Ingle RG, Agarwal AS. A world of low molecular weight heparins (LMWHs) enoxaparin as a promising moiety--a review. Carbohydr Polym. 2014;106:148\u201353.","journal-title":"Carbohydr Polym"},{"issue":"4","key":"4161_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/jp.2009.164","volume":"30","author":"E Friedrich","year":"2010","unstructured":"Friedrich E, Hameed AB. Fluctuations in anti-factor Xa levels with therapeutic enoxaparin anticoagulation in pregnancy. J Perinatol. 2010;30(4):253\u20137.","journal-title":"J Perinatol"},{"issue":"3","key":"4161_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/MBC.0000000000000573","volume":"28","author":"A Boban","year":"2017","unstructured":"Boban A, Paulus S, Lambert C, Hermans C. The value and impact of anti-Xa activity monitoring for prophylactic dose adjustment of low-molecular-weight heparin during pregnancy: a retrospective study. Blood Coagul Fibrinolysis. 2017;28(3):199\u2013204.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"4","key":"4161_CR24","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1097\/AOG.0b013e31818638dc","volume":"112","author":"NS Fox","year":"2008","unstructured":"Fox NS, Laughon SK, Bender SD, Saltzman DH, Rebarber A. Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis. Obstet Gynecol. 2008;112(4):884\u20139.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"4161_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1046\/j.0004-8666.2003.00034.x","volume":"43","author":"JA Rowan","year":"2003","unstructured":"Rowan JA, McLintock C, Taylor RS, North RA. Prophylactic and therapeutic enoxaparin during pregnancy: indications, outcomes and monitoring. Aust N Z J Obstet Gynaecol. 2003;43(2):123\u20138.","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"7","key":"4161_CR26","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1592\/phco.31.7.678","volume":"31","author":"NL Shapiro","year":"2011","unstructured":"Shapiro NL, Kominiarek MA, Nutescu EA, Chevalier AB, Hibbard JU. Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: single-center experience. Pharmacotherapy. 2011;31(7):678\u201385.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"4161_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ejogrb.2011.03.010","volume":"158","author":"SJ Stock","year":"2011","unstructured":"Stock SJ, Walker MC, Edelshain BT, Horn L, Norman JE, Denison FC. Fixed dosing regimes of enoxaparin for thromboprophylaxis do not reliably achieve target anti-Xa levels in women of normal weight during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2011;158(1):112\u20133.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"4161_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jaci.2013.02.047","volume":"132","author":"M Schindewolf","year":"2013","unstructured":"Schindewolf M, Gobst C, Kroll H, Recke A, Louwen F, Wolter M, et al. High incidence of heparin-induced allergic delayed-type hypersensitivity reactions in pregnancy. J Allergy Clin Immunol. 2013;132(1):131\u20139.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"4161_CR29","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.3324\/haematol.2008.002840","volume":"94","author":"J Quinn","year":"2009","unstructured":"Quinn J, Von Klemperer K, Brooks R, Peebles D, Walker F, Cohen H. Use of high intensity adjusted dose low molecular weight heparin in women with mechanical heart valves during pregnancy: a single-center experience. Haematologica. 2009;94(11):1608\u201312.","journal-title":"Haematologica"},{"issue":"9856","key":"4161_CR30","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1016\/S0140-6736(12)60409-7","volume":"380","author":"M Schindewolf","year":"2012","unstructured":"Schindewolf M, Lindhoff-Last E, Ludwig RJ, Boehncke WH. Heparin-induced skin lesions. Lancet. 2012;380(9856):1867\u201379.","journal-title":"Lancet"},{"issue":"1","key":"4161_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/cod.12764","volume":"77","author":"M Schindewolf","year":"2017","unstructured":"Schindewolf M, Recke A, Zillikens D, Lindhoff-Last E, Ludwig RJ. Nadroparin carries a potentially high risk of inducing cutaneous delayed-type hypersensitivity responses. Contact Dermatitis. 2017;77(1):35\u201341.","journal-title":"Contact Dermatitis"},{"issue":"17","key":"4161_CR32","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1056\/NEJMoa1000641","volume":"362","author":"SP Kaandorp","year":"2010","unstructured":"Kaandorp SP, Goddijn M, van der Post JA, Hutten BA, Verhoeve HR, Hamulyak K, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010;362(17):1586\u201396.","journal-title":"N Engl J Med"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-021-04161-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-021-04161-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-021-04161-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T09:11:44Z","timestamp":1633597904000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-021-04161-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,7]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4161"],"URL":"https:\/\/doi.org\/10.1186\/s12884-021-04161-1","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,7]]},"assertion":[{"value":"8 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by by the Institutional Review Board of Ren Ji Hospital. Quantitative data were obtained from retrospective review of HaiTai System and hospital charts. Informed consent was obtained from all study participants. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declared that they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"683"}}